Introduction
============

An early stage node-negative breast cancer (ESNNBC) offers a good prognosis.[@b1-cmar-10-4853] Improved surgical techniques, systemic therapy options, and radiation therapy (RT) have resulted in significant improvement in long-term cause-specific survival.[@b2-cmar-10-4853],[@b3-cmar-10-4853]

Increasing use of RT has resulted in significant increase in long-term survival,[@b2-cmar-10-4853],[@b3-cmar-10-4853] translating to more women at risk of developing long-term treatment-related toxicities. Hence, it is contradictory that the benefits of improved survival, due to the successful delivery of RT for ESNNBC, are negated by RT-induced toxicities.

Dosimetry planning for whole breast external beam radiotherapy (WBEBRT) typically involves a pair of tangential fields to homogenously treat the entire breast while avoiding adjacent vital organs, like the lungs, heart, and left anterior descending artery (LAD).[@b4-cmar-10-4853]

Cardiac toxicity studies demonstrate increased mortality and morbidity from heart disease,[@b5-cmar-10-4853]--[@b8-cmar-10-4853] especially left-sided WBEBRT patients, 10--15 years after receiving irradiation compared to right-sided WBEBRT patients. Recent imaging studies demonstrate consistent occurrence of perfusion defects, microvascular disease, stenosis, and atherosclerosis where the heart and coronary arteries are included in the radiation field and validate the need to reduce cardiac dose.[@b6-cmar-10-4853],[@b7-cmar-10-4853],[@b9-cmar-10-4853]

Lung toxicity studies have demonstrated increased risk of secondary lung cancers and mortality for radiation-induced lung cancer post WBEBRT.[@b5-cmar-10-4853] Grantzau and Over-gaard found that ≥5 years after breast cancer diagnosis, RT was significantly associ ated with an increased risk of radiation-induced lung cancer relative risk (RR) of 1.39 (95% CI 1.28--1.51).[@b10-cmar-10-4853]

Radiation pneumonitis (RP) arises from irradiation of the adjacent ipsilateral lung in breast cancer. It has been reported to be related to 1) the amount of lung irradiated within the tangential fields, 2) use of supraclavicular field, 3) prior exposure to chemotherapy, 4) high-dose chemotherapy, and 5) concurrent tamoxifen medication and smoking habits.[@b11-cmar-10-4853]

Current literature suggests new advanced radiation techniques vis-a-vis delivering and quantifying radiation doses to the organs at risk (OAR).[@b12-cmar-10-4853] Such techniques include 1) maneuvers to achieve maximum separation of the heart from the chest wall (ie, synchronizing RT with the patients' respiratory cycle or prone positioning),[@b13-cmar-10-4853]--[@b15-cmar-10-4853] 2) designing and utilizing cardiac blocks to minimize radiation damage to the heart while avoiding over shielding,[@b16-cmar-10-4853] 3) utilizing advanced technologies for RT delivery (ie, intensity-modulated radiation therapy \[IMRT\] or proton beam radiation therapy \[PBT\]),[@b17-cmar-10-4853],[@b18-cmar-10-4853] and (4) moving away from whole breast volume to partial breast volume treatment (accelerated partial breast irradiation \[APBI\] or intraoperative radiation therapy \[IORT\]).[@b19-cmar-10-4853],[@b20-cmar-10-4853]

This review aimed to evaluate the evidence for each technique by 1) identifying the different breast RT techniques for ESNNBC, 2) collate the dosimetric outcomes for each breast RT technique, and 3) identify the best dosimetric technique.

Methods
=======

Eligible articles include articles about 1) breast cancer RT; 2) RT-associated toxicities, and 3) published in an English language peer-reviewed journal. A systematic search using MEDLINE/PubMed and MeSH headings was used to identify articles addressing RT techniques. The headings were breast cancer, radiation therapy, intensity modulated, prone, partial breast, breath-hold (BH), gating, intraoperative, side effects, heart, cardiac, lung, and pulmonary.

Articles were excluded if they provided pilot data, descriptions of a study design, articles on non-breast cancer data, post-mastectomy radiation, lymph node irradiation, exclusive evaluation of patients with pectus excavatum, bilateral breast irradiation, articles not having heart, LAD, and/or lung dosimetric data or non-English language articles.

Articles were reviewed specifically for data from patients whose left breast was treated. For dosimetric studies, mandatory information included the sample size, techniques used, and outcomes. For clinical studies, mandatory information included sample size reviewed, RT techniques utilized, whether there was a comparison arm, and clinical outcomes (recurrence, toxicities, and pulmonary and/or cardiac outcomes).

Given heterogeneity among studies, OAR dosimetric parameters were evaluated through three different mechanisms. For lung, these mechanisms are 1) anatomic data (ie, volume of lung within irradiated field) and 2) lung dose volume histogram (DVH) data (V~x~ and D~x~). For heart, these mechanisms are 1) anatomic data (ie, volume of heart within irradiated field) and 2) heart DVH data (V~x~ and D~x~). For LAD, 1) anatomic data (ie, volume of LAD within irradiated field) and 2) LAD DVH data (V~x~ and D~x~).

All searches were completed by June 10, 2017.

Results
=======

Six consistently utilized and studied RT techniques were found: 1) prone positioning, 2) PBT, 3) IMRT, 4) BH, 5) partial breast irradiation (PBI), and 6) IORT.

[Table 1](#t1-cmar-10-4853){ref-type="table"} summarizes the mechanism of each RT technique. [Table 2](#t2-cmar-10-4853){ref-type="table"} presents the data supporting each technique and the key dosimetric findings.

Prone technique
---------------

The prone position is a technique where the patient lies on a platform with a modifiable aperture through which the ipsilateral breast hangs away from the thorax by gravity.[@b21-cmar-10-4853]

Lung exposure when lying prone
------------------------------

Literature demonstrates a significant decrease in lung dose in the prone position although the left lung volume was essentially greater in the prone position.[@b22-cmar-10-4853]--[@b26-cmar-10-4853] The breast sits anterior to the lung when the patient is lying prone. This subjects it to the compressive force from the weight of the breast. Lying prone prevents this compression, leading to better expansion of the lung.[@b27-cmar-10-4853] Hence, the decrease in lung dose could be attributed to an increase in the lung volume when lying prone. All prone treatment techniques showed similar lung dose metrics.

This correlates to decreased lung exposure and possibly reduces the risk of radiation-induced lung toxicities. While conventional WBERT in the supine position has been shown to increase the risk of ipsilateral lung carcinoma with a RR of 0.11,[@b28-cmar-10-4853] lying prone could reduce this RR.

Cardiac and LAD exposure when lying prone
-----------------------------------------

With the breast parenchyma falling away from the chest wall, this allows the radiation beam edge to be potentially placed further away from the heart. This increases the heart to chest wall distance and theoretically allows for cardiac dose reduction.[@b20-cmar-10-4853],[@b29-cmar-10-4853]

NYU trial studied both the supine and prone positions and found that 85% of the patients with left breast target lesions demonstrated a reduction of in-field heart volume by a mean of 11 cc.[@b30-cmar-10-4853] A recent similar trial, consisting of 53 patients with left breast cancer also demonstrated similar results where 87% had a 12 cc mean reduction of in-field heart volume.[@b22-cmar-10-4853] However, the reduction of in-field heart volume due to the prone technique is an inconsistent finding as a comparatively small percentage of patients still benefit from the supine position compared to the prone position.[@b22-cmar-10-4853],[@b30-cmar-10-4853],[@b31-cmar-10-4853]

Kirby et al found an increase in heart dose in eight of 30 patients receiving whole breast irradiation, with a median increase in LAD~mean~ of 9.5 Gy.[@b24-cmar-10-4853] Mulliez et al analyzed supine vs prone plans for 18 patients.[@b32-cmar-10-4853] The results demonstrated no significant improvement in heart sparing with the prone position. Würschmidt et al suggested that cardiac and LAD exposure might inadvertently increase due to the anterior movement of the heart when lying prone for WBEBRT.[@b33-cmar-10-4853] There was no difference in the mean heart dose for left WBE-BRT in the prone (4.16 Gy, 95% CI 3.5--4.9 Gy) and supine positions (4.01 Gy; 95% CI 3.4--4.6 Gy; *P*=0.7). However, the LAD received a significantly higher mean dose and no improvement in the maximum dose in the prone position. For the left breast prone WBEBRT, the LAD received a significantly higher average mean dose (33.5 Gy; 95% CI 29.5--37.4 Gy) compared to left supine WBEBRT (25.6 Gy; 95% CI 21.4--29.7 Gy; *P*=0.0051). The average mean maximum dose was comparable (*P*=0.766) between supine WBEBRT (43.2 Gy; 95% CI 39.14--47.19 Gy) and prone WBEBRT (43.9 Gy; 95% CI 40.73--47 Gy).

Hence, cardiac and coronary artery benefits for prone position remains controversial with conflicting results.[@b22-cmar-10-4853],[@b29-cmar-10-4853],[@b30-cmar-10-4853],[@b33-cmar-10-4853]--[@b35-cmar-10-4853] This could be due to varying contouring and treatment techniques among the different institutions.

Concerns regarding the prone technique
--------------------------------------

Concerns regarding decreased reproducibility of the prone position and poor set up from patient discomfort may lead to greater potential for increased dose to normal tissues.[@b20-cmar-10-4853],[@b36-cmar-10-4853] However, Jozsef et al demonstrated that reproducibility of the prone position is improved with cone beam CT.[@b37-cmar-10-4853] This is at the expense of additional irradiation.[@b38-cmar-10-4853]

While early studies postulate poorer cosmetic outcomes with the prone technique from risk of erythema, recent research have proven comparable or better outcomes compared to the supine technique.[@b23-cmar-10-4853],[@b39-cmar-10-4853],[@b40-cmar-10-4853]

Stegman et al conducted the largest long-term study with a cohort of 245 patients and a median follow-up of 4.9 years.[@b41-cmar-10-4853] The prone position resulted in similar long-term disease control with a favorable toxicity profile compared with standard supine tangents. However, it can only be postulated that the anatomic advantage of prone positioning may contribute to improving the therapeutic ratio of post-lumpectomy radiation by improving dose homogeneity and minimizing incidental cardiac and lung dose. Long-term follow-up studies evaluating cardiac and pulmonary outcomes are needed.

Current scenario
----------------

Although the evidence for lung sparing is clear, the value of cardiac and LAD sparing remains equivocal. Subset analyses suggest large-breasted patient generally benefit more from the prone position compared to small-breasted patients.[@b40-cmar-10-4853],[@b41-cmar-10-4853]

PBT
---

The potential of PBT lies in its unique physical dose-deposition properties that allow maximum dose deposition within the tumor and rapid dose fall off beyond the Bragg peak. This potentially reduces adjacent OARs and subsequently toxicities incurred.[@b42-cmar-10-4853]--[@b45-cmar-10-4853]

### Lung, heart, and LAD exposure when utilizing PBT

Dosimetric studies demonstrate dose reduction to the OARs.[@b42-cmar-10-4853],[@b43-cmar-10-4853],[@b45-cmar-10-4853] Lin et al demonstrated significant reductions to high and low doses to the lung, heart, and LAD where lung V~20\ Gy~ (photon vs proton: 12.5% vs 0%, *P*\<0.0167), lung V~5\ Gy~ (photon vs proton: 25.2% vs 4.7%, *P*\<0.0167), lung D~mean~ (photon vs proton: 27.3 vs 0.88 Gy, *P*\<0.0167), heart V~20\ Gy~ (photon vs proton: 0.7% vs 0%, *P*\<0.0167), heart V~5\ Gy~ (photon vs proton: 4.3% vs 0%, *P*\<0.0167), heart D~mean~ (photon vs proton: 1.6 vs 0.011 Gy, *P*\<0.0167), LAD D~min~ (photon vs proton: 1.1 vs 0 Gy), LAD D~max~ (photon vs proton: 31.8 vs 0.71 Gy, *P*\<0.0167), and LAD D0.2 cc (photon vs proton: 10 vs 0.052 Gy, *P*\<0.0167). This could be attributed to the physical properties of PBT.

### Concerns regarding PBT

Although the merits of PBT lie in its potential to reduce radiation-induced morbidities, a prevalent concern underlying the widespread adoption of PBT is its significant cost. Proponents for the adoption of breast PBT argue that two emerging issues may increase the cost-effectiveness for breast PBT. First, as technology rapidly advances and efficiency in delivery improves, costs will become more manageable. Second, the cost of PBT can be further reduced with the adoption of hypofractionated regime.

### Current scenario

The advantageous dose distribution and excellent OAR sparing that can be achieved coupled with growing experience with PBT makes PBT an attractive option. However, data on PBT for breast remains sparse and costs remain significantly high. Given limited data and uncertainty in estimating the cost--benefits, judicious adoption of PBT is recommended.

IMRT
----

IMRT is the utility of multileaf collimator (MLC) technology to shape and create non-uniform intensity of radiation beams as it transverse through the patient's body.[@b46-cmar-10-4853],[@b47-cmar-10-4853] By varying the speeds at which the MLC leaves travel or the shape of the beam, the radiation beam is effectively shaped to vary the dose distribution to the target volume.[@b47-cmar-10-4853]

In recent decades, IMRT has emerged as a revolutionary concept that irradiates the tumor more precisely while relatively sparing dose to adjacent OARs. The main advantage of IMRT is that it allows dose painting.[@b46-cmar-10-4853]

### Lung, heart, and LAD exposure with IMRT

OARs dose reductions with IMRT are contradictory. For example, Schubert et al demonstrated significant reductions in lung V~20\ Gy~ (three-dimensional conformal radiotherapy \[3D CRT\] vs IMRT: 14.8% vs 11.8%, *P*\<0.001), lung V~5\ Gy~ (3D CRT vs IMRT: 28.1% vs 24.1%, *P*\<0.001), and lung D~mean~ (3D CRT vs IMRT: 8.1 vs 6.6 Gy, *P*\<0.001).[@b48-cmar-10-4853] However Haciislamoglu et al demonstrated instead a significant increase in lung V20 Gy (3D CRT vs IMRT: 12.99% vs 16.64%, *P*=0.005), lung V~5\ Gy~ (3D CRT vs IMRT: 19.8% vs 79.92%, *P*\<0.001), and lung D~mean~ (3D CRT vs IMRT: 7.66 vs 12.18 Gy; *P*\<0.001).[@b49-cmar-10-4853] Conflicting results have also been demonstrated for both the heart and the LAD.

More than 50% of the articles demonstrated a reduction in high doses and an increase in low doses to the OARs. This increase in low dose could be attributed to two factors: 1) the number of monitor units increases which results in increase in total body radiation dose and 2) IMRT utilizes more fields resulting in greater volume of normal tissues exposed to low radiation doses.[@b50-cmar-10-4853],[@b51-cmar-10-4853] Theoretically, an increase in low dose exposure leads to increased rates of radiation-induced secondary malignancies.[@b49-cmar-10-4853] Compared to 3D CRT, IMRT can potentially increase the incidence of solid secondary cancers due to a combination of changed dose distribution and increase in monitor units. As radiation-induced carcinogenesis is due to the stochastic effect of normal tissue radiation exposure, it is imperative that strategies to decrease OAR dose without compromising adequate dose coverage are implemented.

### Concerns regarding IMRT

Of concern is the conundrum posed by involuntary tumor and patient movement. As in all IMRT cases, the planning target volume (PTV) drawn must encompass all known diseases. This means that all possible movements by both the tumor and the patient should be accounted for. An inappropriate margin will result in underdosing of the tumor and/or overdosing of the surrounding OAR. Hence, extra caution should be taken to limit patient movement with an appropriate reproducible patient immobilization.[@b46-cmar-10-4853]

Another conundrum is the existence of conflicting data regarding the dosimetric superiority of IMRT over 3D CRT. Compared to prone and breathing techniques, the dosimet-ric benefits of IMRT proved inconsistent in reducing lung, heart, and LAD doses and its associated NTCPs. Although literature suggests that IMRT is not routinely advantageous, IMRT can prove useful for patients with atypical anatomy such as severe pectus excavatum.[@b52-cmar-10-4853]

### Current scenario

IMRT represents an often-used technique in a clinical setting with conflicting data with respect to OAR dose reduction. IMRT can also be utilized with breathing techniques, prone technique, and PBI.

BH
--

Respiratory maneuvers, primarily utilized for cardiac dose reduction, have been picking up over the past decades.[@b53-cmar-10-4853]--[@b55-cmar-10-4853] Respiratory maneuvers such as inspiration pulls the heart and diaphragm inferiorly while expanding the thoracic cav ity.[@b53-cmar-10-4853]--[@b55-cmar-10-4853] This increases the heart to chest wall distance. As radiation-induced heart toxicities correlates to the in-field heart volume within the radiation fields, respiratory maneuvers that reduces in-field heart volume shows promise in reducing radiation dose to the heart while allowing adequate dose to the breast. Later studies affirmed that deep inspiration breath-hold (DIBH) represents the optimum point of heart displacement.[@b56-cmar-10-4853] With the development of more sustainable and reproducible methods, multiple studies were conducted comparing free breathing (FB) vs DIBH.

### Lung exposure with BH

Conflicting results regarding lung dose reduction with DIBH exists with multiple studies demonstrating an increase in lung dose with BH. Remouchamps et al demonstrated a significant increase in V20 Gy (DIBH vs FB: 20.4% vs 15.2%, *P*\<0.00007) with DIBH.[@b56-cmar-10-4853] However, recent studies have also demonstrated comparable or nonsignificant increases in lung doses with DIBH.[@b57-cmar-10-4853],[@b58-cmar-10-4853] There are two possible reasons why DIBH results in the increase in lung dose. First, during DIBH, the lungs expand and hence increase in volume. Furthermore, with the displacement of the heart away from the chest wall, this increases the absolute lung volume within the radiation fields. Hence, the significant increase of in-field lung volume correlates to an increase in lung doses. Both Walston et al and Mulliez et al demonstrated an increase in lung volume (DIBH vs FB: 2,059.39 cc vs 1,181.34 cc, *P*\<0.05 and DIBH vs FB: 2,090 cc vs 1,235 cc, *P*\<0.001) with DIBH, respectively.[@b57-cmar-10-4853],[@b59-cmar-10-4853] Second, the maturation of technology has allowed MLCs to be employed for customized shielding of normal lung tissue.[@b60-cmar-10-4853] Hence, although the expansion in lung volume with DIBH is inevitable, the correlated significant increase in lung dose can be mitigated with the use of MLCs.

### Cardiac and LAD exposure with BH

The reduction of in-field heart volume of the heart has allowed for a significant DVH reduction, for the heart and LAD, with DIBH.

Nissen and Appelt demonstrated a 91% reduction in V40 Gy (DIBH vs FB: 3.4% to 0.3%, *P*\<0.0001) and a 48% reduction in D~mean~ (DIBH vs FB: 5.2 vs 2.7 Gy, *P*\<0.0001) for left-sided breast plans.[@b61-cmar-10-4853] This improvement in cardiac dose reduction was replicated in a prospective trial conducted by Eldredge-Hindy et al.[@b62-cmar-10-4853] Significant reductions in heart DVHs such as D~mean~ (DIBH vs FB: 0.9 vs 2.7 Gy, *P*\<0.0001), D~max~ (DIBH vs FB: 27.9 vs 50.4 Gy, *P*\<0.0001), V~25\ Gy~ (DIBH vs FB: 0% vs 2.7%, *P*\<0.0001), and V~5\ Gy~ (DIBH vs FB: 3% vs 11.1%, *P*\<0.0001) were established.[@b62-cmar-10-4853] These results confirm earlier cardiac imaging findings demonstrating left ventricular dose reduction with DIBH.[@b63-cmar-10-4853]--[@b65-cmar-10-4853]

The LAD descends along the caudal aspect of the heart and is situated in the vicinity of the radiation fields even in BH plans. Hence with BH, greater significant reductions to the LAD DVHs can be expected. However, greater significant reductions to the LAD DVHs can be expected. Mast et al, utilizing a DIBH device known as active breathing coordinator (ABC) to perform DIBH, demonstrated significant reductions in the LAD DVHs such as D~mean~ (ABC vs FB: 9.6 vs 18.6 Gy, *P*\<0.01), D~max~ (ABC vs FB: 25.2 vs 35.5 Gy, *P*\<0.01), V~20\ Gy~ (ABC vs FB: 17.8% vs 42.5%, *P*\<0.01), and V~5\ Gy~ (ABC vs FB: 39.4% vs 62.6%, *P*\<0.01) with ABC.[@b66-cmar-10-4853] When used in combination with IMRT, further reduction in dose was achieved, D~mean~ (ABC vs FB: 6.7 vs 14.9 Gy, *P*\<0.01), D~max~ (ABC vs FB: 18.8 vs 31.4 Gy, *P*\<0.01), V20 Gy (ABC vs FB: 30.3% vs 54.9%, *P*\<0.01), and V~5\ Gy~ (ABC vs FB: 9.7% vs 32.8%, *P*\<0.01). Further reduction was demonstrated with IMRT due to a rotation in collimator angle which allowed the MLCs to better shield the heart.

### BH versus respiratory gating

Two techniques frequently used for breathing cycle management are DIBH and respiratory gating.

DIBH can be device assisted, that is, by using ABC or performed voluntarily. A Phase III randomized trial by Bartlett et al sought to determine whether voluntary DIBH (vDIBH) and ABC result in a discrepancy in normal tissue sparing, set up reproducibility and feasibility of delivery.[@b67-cmar-10-4853] In terms of normal tissue dose, Bartlett et al found no statistical significance in techniques (all *P* Nonsignificant). Furthermore, positional reproducibility and feasibility of delivery were also comparable.[@b67-cmar-10-4853]

Respiratory gating tracks the respiratory cycles of the patient with thoraco-abdominal sensors to trigger radiation delivery based on the respiratory phase.[@b68-cmar-10-4853],[@b69-cmar-10-4853] Giraud et al evaluated 233 patients and found comparable and consistent reduction in heart DVHs.[@b63-cmar-10-4853]

Currently, only limited data are available to determine the superiority of one breathing technique over another. However, the wealth of literature with respect to BH has affirmed its efficacy and feasibility in treatment delivery and dose reduction to OARs.

A reduction in doses to the OARs correlates to reduction in associated radiation-induced OAR toxicities and mortality. Korreman et al evaluated the radiobiological implications of dosimetric benefits offered with breathing techniques and found significant potential.[@b70-cmar-10-4853] Corresponding pneumonitis probability dropped from 28.1% (range: 0.7%--95.6%) with FB to 2.6% (range: 0.1%--40.1%) with respiratory gating and to 4.3% (range: 0.1%--59%) with DIBH. Likewise, cardiac mortality probability dropped from 4.8% (range: 0.1%--23.4%) with FB to 0.5% (range: 0.1%--2.6%) with respiratory gating and to 0.1% (range: 0%--3.0%) with DIBH.

### Current scenario

BH is undoubtedly one of the most well-studied RT techniques. It can be offered to all patients except patients unable to sustain BH or who have poor respiratory function. BH can also be used in combination with IMRT.

PBI
---

PBI is an alternative RT technique that utilizes hypofractionation regimes for selected patients with early stage breast cancer. Patient selection is based on a review of clinical and pathological factors.[@b4-cmar-10-4853] As only the lumpectomy cavity and a margin around it is irradiated, patient selection is the foremost factor. This includes assessing presurgical and surgical tumor staging to exclude patients at a greater risk of locoregional recurrence.[@b71-cmar-10-4853] Hence, with a reduced irradiated volume, it can be expected that OARs doses decrease.

Increased fraction size results in increased radiobiological equivalent dose to the tumor. However, this is also at the expense of late responding fraction-sensitive OARs, such as the lungs and heart, receiving incidental radiation at an increased dose per fraction too. Hence, a concern regarding a hypofractionation regime associated with PBI is the potential to increase the risk of lung and heart toxicities due to the low α/β of these tissues. The clinical aftermath of receiving higher dose per fraction of incidental radiation to these OARs is as yet unknown. Current data show that toxicities associated with hypofractionation in breast RT have not been correlated with increased OAR-related toxicities.[@b72-cmar-10-4853],[@b73-cmar-10-4853]

### Cardiac and pulmonary exposure with different types of PBI

APBI is a form of PBI which can be delivered via interstitial devices, applicators, or with external beam.[@b20-cmar-10-4853]

The case for APBI lies in that a rare 3%--4% of cases report ipsilateral breast recurrences in areas away from the tumor bed.[@b74-cmar-10-4853] Based on this evidence, WBEBRT may constitute overtreatment as it incorporates the entire breast (inclusive of the surgical cavity), overlying skin, lower axilla, and portions of the heart, lung, and LAD in the treatment fields. Even with modern WBEBRT, unavoidable OAR toxicities are still introduced where APBI can effectively spare more of these OARs. Thus, the theoretical advantage of APBI is its reduced dose to normal tissues as it can be expected that with a reduced target volume, adjacent OARs such as lungs, heart, and LAD will receive less radiation.

Recent long-term studies have attested the clinical efficacy of APBI with excellent local control, toxicities, and cosmesis that are comparable or reduced compared to WBEBRT.[@b75-cmar-10-4853]--[@b77-cmar-10-4853]

With interstitial APBI, multiple catheters are inserted and loaded around the lumpectomy cavity.[@b75-cmar-10-4853] Utilizing high dose rate (HDR) brachytherapy, the target volume receives a high dose away from the chest wall. Applicator-based APBI similarly employs HDR brachytherapy while limiting the dose to the chest wall and adjacent OARs too.[@b78-cmar-10-4853] With external beam APBI (EB-APBI), target volume margins are further enlarged to account for respiratory motions and treatment setup uncertainties not typically associated with brachytherapy. Multiple noncoplanar fields are optimally arranged to limit dose to the OARs.[@b79-cmar-10-4853]

Multi-catheter interstitial brachytherapy has the longest follow-up of any APBI technique to date. Modern image-guided techniques have demonstrated reduced OAR doses.[@b80-cmar-10-4853],[@b81-cmar-10-4853] Multiplane interstitial APBI plans were evaluated for 49 patients. The mean heart dose was found to be 21% of the prescribed dose and a mean V~5~ of 12.8 cc for left-sided breast cancer patients.[@b81-cmar-10-4853] These findings are consistent with Lettmaier's et al study that compared interstitial APBI with standard WBEBRT.[@b82-cmar-10-4853] Lettmaier et al demonstrated that interstitial APBI was consistent in reducing both high and low doses to the OARs; 1) heart D~0.1\ cc~ (APBI vs WBEBRT: 12.59 vs 45.60 Gy, *P*\<0.01), heart D~50\ cc~ (APBI vs WBEBRT: 5.60 vs 18.17 Gy, *P*\<0.01); 2) lung D~0.1\ cc~ (APBI vs WBEBRT: 19.61 vs 51.99 Gy, *P*\<0.01), lung D~50\ cc~ (APBI vs WBEBRT: 8.19 vs 43.38 Gy, *P*\<0.01).[@b82-cmar-10-4853]

In recent years, applicator-based brachytherapy has been gaining traction. Stewart et al performed a dosimetric analysis comparing balloon-based APBI to WBEBRT and found significant reduction in OAR doses too: 1) heart D~max~ (APBI vs WBEBRT: 16.6 vs 44.1 Gy, *P*\<0.05), heart V~20\ Gy~ (APBI vs WBEBRT: 0.1% vs 3.7%, *P*\<0.05); 2) lung D~max~ (APBI vs WBEBRT: 31.0 vs 51.6 Gy, *P*=0.06), lung V~20\ Gy~ (APBI vs WBEBRT: 1.3% vs 10.0%, *P*\<0.05).[@b83-cmar-10-4853] With the introduction of multi-lumen applicators, doses can be better sculpted around the target volume to allow further reductions from the OARs.[@b78-cmar-10-4853],[@b84-cmar-10-4853]

With EB-APBI, the reduction in OAR doses was significantly dependent on the distance from the lumpectomy region. For example, Kron et al found that when lumpectomy regions are \>4 cm away from the heart, the corresponding V~5\ Gy~ would be typically \<1%.[@b85-cmar-10-4853]

Multiple studies have affirmed that techniques such as IMRT, BH, PBT, and prone technique, utilized in WBEBRT can be incorporated with APBI to achieve greater OAR dose reduction. Wu et al compared IMRT-APBI and IMRT-WBEBRT and found significant reductions in lung and heart DVHs. Lung D~mean~ was reduced by a factor of 2 (IMRT-APBI vs IMRT-WBEBRT: 3.17 vs 6.62 Gy, *P*\<0.05) and lung V~20\ Gy~ was reduced by a factor of 6 (IMRT-APBI vs IMRT-WBE-BRT: 1.97 vs 11.77 Gy, *P*\<0.05).[@b86-cmar-10-4853] Likewise, heart D~mean~ was reduced by a factor of 4 (IMRT-APBI vs IMRT-WBEBRT: 0.8 vs 3.17 Gy, *P*\<0.05) and heart V20 Gy was reduced by a factor of 96 (IMRT-APBI vs IMRT-WBEBRT: 0.03 vs 2.88 Gy, *P*\<0.05). Moran et al conducted a Phase I/II study evaluating the dosimetric impact of APBI with BH.[@b87-cmar-10-4853] With BH, lung D~max~ (FB-APBI vs BH-APBI: 38.1 vs 35.5 Gy, *P*\>0.001) and D~mean~ (FB-APBI vs BH-APBI: 2.9 vs 1.7 Gy, *P*\>0.001) was further reduced. Likewise, heart D~max~ (FB-APBI vs BH-APBI: 8.2 vs 4.8 Gy, *P*\>0.001) and D~mean~ (FB-APBI vs BH-APBI: 0.5 vs 0.4 Gy, *P*\>0.001) was further reduced. Galland-Girodet et al conducted a prospective study to compare the impact of photons vs proton on APBI OAR dosimetry.[@b88-cmar-10-4853] With proton, lung D~max~ (photon-APBI vs proton-APBI: 28.9 vs 20.4 Gy, *P*\<0.0001) and Dmean (photon-APBI vs proton-APBI: 2.2 vs 0.5 Gy, *P*\<0.0001) were further significantly reduced. With proton, heart D~max~ (photon-APBI vs proton-APBI: 7.7 vs 3.8 Gy, *P*\<0.0001) and D~mean~ (photon-APBI vs proton-APBI: 0.9 vs 0.0 Gy, *P*\<0.0001) was further significantly reduced. EB-APBI can also be delivered in the prone position. Prospective trials have demonstrated that EB-APBI is compliant to dosimetric requirements.[@b89-cmar-10-4853],[@b90-cmar-10-4853] However, Formenti et al found that prone EB-APBI resulted in an increase in cardiac dose in 19 of 30 plans compared to a decrease in cardiac dose in seven of 30 plans.[@b89-cmar-10-4853]

In essence, EB-APBI allows for excellent lung and heart dose reduction. However, recent interim cosmetic and toxicities results of EB-APBI from the Canadian RAPID trial have demonstrated that current prescribed fractionation regime for EB-APBI approaches the steep aspect of the toxicity curve and cautions against adopting it as standard practice.[@b91-cmar-10-4853]

### Current scenario

APBI is an effective alternative to WBEBRT in the management of carefully selected patients with early stage breast cancer or ductal carcinoma in situ based on recently published consensus guidelines.[@b77-cmar-10-4853] As EB-APBI approaches the steep aspect of toxicity curve, we do not advocate the adoption of EB-APBI as standard practice.

IORT
----

IORT represents an alternative to postoperative irradiation as it delivers radiation at the time of surgery as a single fraction in most cases. IORT is increasingly offered as definitive RT following breast conserving surgery. Currently, data on IORT remains far more limited than APBI.[@b92-cmar-10-4853]--[@b96-cmar-10-4853] IORT can be delivered via electrons utilizing lead shielding to reduce dose beyond chest wall.[@b95-cmar-10-4853]--[@b98-cmar-10-4853] Aziz et al compared the dosimetric gains of utilizing IORT compared to APBI and WBEBRT and demonstrated a reduction of D~mean~ from 3.4 to 0.13 and 0.03 Gy with WBEBRT, APBI, and IORT, respectively.[@b99-cmar-10-4853] Lung D~max~ was likewise reduced from 53.0 to 7.4 and 1.8 Gy with WBEBRT, APBI, and IORT, respectively. Similar findings were also demonstrated for heart dose where heart D~mean~ was reduced from 1.00 to 0.06 and 0.01 Gy with WBEBRT, APBI, and IORT, respectively. Although dosimetric gains achieved with IORT are certainly promising, IORT is not without its controversy.

Two large randomized trials were undertaken to compare the efficacy of IORT in early stage breast cancer with WBEBRT. The targeted intraoperative radiotherapy (TAR-GIT) trial found that one-fifth of the IORT cohort needed WBEBRT supplementation and was further associated with an inferior local control at 5 years (3.3% vs 1.3%, *P*=0.04).[@b95-cmar-10-4853] Similarly, the intraoperative radiotherapy with electrons (ELIOT) trial demonstrated a significantly higher 5-year ipsilateral breast tumor recurrence compared to the WBEBRT arm (4.4% vs 0.4%, *P*=0.0001).[@b96-cmar-10-4853] Based on these data, IORT as definitive treatment is discouraged.

### Current scenario

In view of higher rates of local recurrence with IORT and inadequate data to support its safety, efficacy, and widespread adoption compared to WBEBRT or APBI, IORT is discouraged.

Discussion
==========

Breast-conserving surgery with adjuvant RT is the standard treatment for ESNNBC. A recent meta-analysis found that in women with pN0 disease, RT reduced these risks from 31.0% to 15.6% (absolute recurrence reduction 15.4%, 13.2--17.6, 2*P*\<0.00001) and from 20.5% to 17.2% (absolute mortality reduction 3.3%, 0.8--5.8, 2*P*=0.005), respectively.[@b100-cmar-10-4853] With many long-term survivors, treatment-induced toxicities are a major consideration. Concerns regarding the necessity of whole breast irradiation, treatment-associated toxicities, quality of life (QOL) based on these treatments are the subjects of current clinical trials.

Data from population studies and older literature have shown increase in heart, lung, and LAD morbidity and mortality.[@b7-cmar-10-4853],[@b8-cmar-10-4853],[@b101-cmar-10-4853] While pulmonary and cardiac toxicities affect the patients' QOL, it is the cardiac toxicities that have a greater potential to become lethal. Hence, patients with left-sided breast cancer should be offered some form of heart dose sparing technique.

The literature search resulted in six RT techniques that have been consistently utilized and studied: 1) prone positioning, (2) PBT, (3) IMRT, (4) BH, (5) PBI, and (6) IORT ([Table 1](#t1-cmar-10-4853){ref-type="table"}).

Of these techniques, PBT and PBI have consistently reduced OAR doses. The other techniques have demonstrated dose reduction to OARs in most cases, with some cases reporting an increase in OAR doses ([Table 2](#t2-cmar-10-4853){ref-type="table"}).

APBI has consistently demonstrated great reductions in both high and low dose for the lungs, heart, and LAD. These reductions are possible as APBI only irradiates the lumpectomy region compared to WBEBRT.[@b20-cmar-10-4853] When examining all APBI techniques, EB-APBI demonstrates many advantages over other techniques.[@b102-cmar-10-4853] First, EB-APBI is non-invasive. This potentially reduces the risk of invasive complications. Second, EB-APBI allows for widespread adoption as most centers are already performing 3D-CRT for other cancers. Third, adopting EB-APBI may be hassle-free compared to adopting brachytherapy APBI techniques as technical and quality assurance needs of external beam are much simpler. Fourth, treatment outcomes with EB-APBI may be more uniform across centers as the outcome is less operator dependent. Disadvantages of EB-APBI include errors contributed by breathing motions, treatment setup variation, and fractionation regime.

Fractionation regime for EB-APBI remains questionable. Multiple studies demonstrate different fractionation scheme and concerns regarding the steep aspect of the toxicity curve, thus cautions against its widespread adoption.[@b91-cmar-10-4853],[@b103-cmar-10-4853]

However, the other APBI techniques which fall under the branch of brachytherapy can be safely delivered well within acceptable toxicity standards while achieving comparable OAR dose reduction. The premise of brachytherapy lies in the inverse square law inherent to radioactive sources which allows the delivery of high tumoricidal radiation dose within the tumor bed with substantial sparing of the normal surrounding tissues.[@b104-cmar-10-4853] Despite interstitial brachytherapy being a surgical procedure, it presents many advantages too. Reasons to decline standard adjuvant WBEBRT RT include traveling to radiation facilities, daily transport issues, old age, or physical handicap.[@b105-cmar-10-4853],[@b106-cmar-10-4853] Brachytherapy APBI may allow such patients to receive standard breast conserving treatment. Brachytherapy APBI, which can be completed over 4--5 days, potentially allows all localized therapy to be completed before the start of systemic therapy. This is crucial for local control as patients will need to undergo 4--6 months of chemotherapy prior to adjuvant breast RT. A disadvantage of brachytherapy APBI is the availability of brachytherapy APBI as a service in the radiation facility which the patient visits.

IORT is technically PBI. However, unlike other APBI techniques, radiation is delivered as a single fraction at the time of lumpectomy.[@b107-cmar-10-4853] This makes it an attractive alternative to standard WBEBRT or APBI. IORT is increasingly offered as definitive RT during breast conserving surgery. This is alarming as the pathological and nodal statuses are not reviewed prior to the administration of IORT. Furthermore with limited data supporting its safety and efficacy compared to other RT techniques, IORT is essentially an off-protocol treatment. Beyond clinical data, there exist significant concerns regarding the radiobiology and physics of IORT techniques. With respect to IORT utilizing 50 kv X-ray source, although the surface dose is 20 Gy, the dose is drastically attenuated to 5 Gy, as a single dose, at 1 cm from the source surface distance. This sharply contrasts against a typical APBI plan that delivers 3.4 Gy to the PTV. Hence, it is unsurprising that randomized trials report higher rates of local recurrence.[@b108-cmar-10-4853] Another significant concern is the lack of image guidance. Without it, identification and documentation of the precise location of dose delivery and dose received by OARs remain to be an estimation at best.

While IORT may appear promising, in view of poor clinical outcomes compared to standard WBEBRT, improper adherence to standard radiobiological principles in breast RT and a lack of proper standardized protocols for delivery, clinical data do not support the routine use of IORT.

Where APBI is unavailable or unsuitable, cardiac avoidance techniques with WBEBRT should be explored. A difference in setup position can aid in OAR reduction.[@b29-cmar-10-4853] However, from the above data, it is found that OAR dose reduction is inconsistent with the prone position. Also, the prone position requires special immobilization gadgets that may not be available in all centers.

IMRT is consistent in minimizing high dose to the heart, lungs, and LAD. However, the integral dose to these organs, the thorax and the contralateral breast, is often increased with uncertain clinical consequence. Another merit of IMRT is improved breast cosmesis.[@b109-cmar-10-4853] Patients who are well endowed benefit most from IMRT.

The rapid dose fall off beyond the Bragg peak of the proton beam allows for great reductions to OARs beyond the target volume. However, PBT is a significantly expensive treatment and may not be economically attractive despite its consistent reduction in high and low dose to OARs ([Table 2](#t2-cmar-10-4853){ref-type="table"}).

Patients who are suitable candidates for BH should be offered if available. BH like PBT consistently reduces high and low doses to heart. However, this is not consistently so for dose to the lungs. All BH delivery methods reduces dose to the heart. The dosimetric advantages with BH are encouraging. However, there remain two aspects of BH that needs further research.[@b15-cmar-10-4853] First, no clear selection criteria exist to identify which patient group will benefit most from BH other than the left-sided breast cancer patients. Currently, evidence suggests that parasagittal cardiac contact to the chest wall may be a suitable metric for BH selection. Second, the success of BH delivery is heavily dependent on patient's compliance and treatment verification. These are additional areas that can be explored further together with coaching strategies.

The impairment of lung function is primarily dependent on the proportion of lung volume receiving a dose beyond its tolerance dose.[@b110-cmar-10-4853] Hence, although the lung is one of the most sensitive late responding organ, because of its functional units, only when large volumes of the lungs are irradiated does the lung become a dose-limiting organ.

Lung is inadvertently irradiated during breast RT. Although Lind et al had reassured that RP is an infrequent complication after local WBEBRT (0.9%), it is important to bear in mind that the incidence of RP increases with increase in age, concurrent tamoxifen, and prior chemotherapy.[@b111-cmar-10-4853] Smoking habits and pre-RT performance status are also important factors in determining the incidence and severity of RP.

Given the anatomical location of heart, potential cardio-toxicity is associated with RT to the left breast. The incidence of ischemic heart disease has been correlated to the volume of heart irradiated and radiation dose received.[@b5-cmar-10-4853],[@b6-cmar-10-4853] Although these effects were dominant in early studies based on outdated RT techniques, they serve as a reminder to always minimize cardiac dose where possible. The dosimetric outcomes of clinical studies utilizing modern techniques suggest superior outcomes and a potential decrease in cardiac complications in future long-term follow-up studies. Clinical evidence suggests that radiation to the heart has detrimental consequences despite latencies are estimated to become detectable at only \>15 years after radiation treatment.[@b112-cmar-10-4853]

The meta-analysis of the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) found that the gain in locoregional control did not fully translate to an improvement in overall survival.[@b113-cmar-10-4853] This was due to life-threatening side effects associated with older RT regimens. The EBCTCG trial reported a significant excess (SE) incidence of contralateral breast cancer (rate ratio 1.18, SE 0.06, 2*P*=0.002) and a SE of non-breast-cancer mortality in irradiated women (rate ratio 1.12, SE 0.04, 2*P*=0.001) at 15 years after breast RT. The mortality was attributed to cardiovascular disease (rate ratio 1.27, SE 0.07, 2*P*=0.0001) and lung cancer as a secondary malignancy (rate ratio 1.78, SE 0.22, 2*P*=0.0004). This suggests that the survival benefit supposedly conferred with adjuvant breast RT was partially negated by the increase in cardiovascular-related death and lung cancer as a secondary malignancy. Therefore, this reinforces that reducing heart and lung irradiation should be a critical aspect in selecting the most appropriate radiation technique for the patient and radiation treatment planning. Patient factors like anatomy, tumor location, its anatomical relation to OAR, and breast contour should be borne in mind when deciding on the most appropriate RT technique.

Current data recommend that where possible and suitable, patients should be first offered PBI. The next best option for OAR dose reduction would be BH.

Long-term studies are needed to evaluate the effect of RT on the heart, LAD, and lungs with modern RT techniques in both the acute and late settings. This could also be particularly helpful in advising patients on lifestyle modification in cases of increased radiation-induced toxicity risks.

Conclusion
==========

As RT techniques evolve, the focus on survival, control, recurrence, and tissue toxicities remains. Treatment options have to take into consideration patient's schedule, QOL, and the financial impact of different techniques.

Currently, in terms of whole breast irradiation, dosimetric data suggest that BH techniques allow for consistent cardiac dose reduction at the expense of slight increase in lung doses. This is in contrast to techniques such as the prone position and IMRT. Although PBT achieves consistent OAR dose reduction too, the sheer significantly higher cost makes it unaffordable for most patients. In terms of PBI, APBI has comparable survival, control, and recurrence outcomes with even better cosmesis. IORT is cautioned against in view of its high failure rate and limited data. Among the various radiotherapy modalities, current evidence suggests that PBI multicatheter offers the best heart and lung dosimetry.
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###### 

RT techniques

  RT technique                 Mechanism of technique
  ---------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Prone positioning            Breast falls away from the chest wall thereby increasing the distance of the OARs to the RT beam
  Proton beam therapy          Unlike the properties of photons, protons allow for a steep dose fall off
  Intensity-modulated RT       Utilizing dose planning algorithms and computerizing each individual leaf position of the multileaf collimator to shape the radiation field away from the OARs
  Breath-hold                  Utilizing respiratory inspiration to achieve maximum separation from heart to chest wall
  Partial breast irradiation   Smaller target volume theoretically decreases OAR dose
  Intraoperative RT            Smaller target volume and sometimes utilizing lower energies to reduce OAR dose

**Abbreviations:** RT, radiation therapy; OAR, organ at risk.

###### 

Summary of studies on lung, cardiac, and LAD dose reduction

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  RT technique     Key findings (lung)                                                                                                                   Lung dose reduction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         Key findings (cardiac)                                                                                                                                          Cardiac dose reduction                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Key findings (LAD)                                                                                                                                          LAD dose reduction
  ---------------- ------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Prone position   1\. All studies demonstrated a reduction in lung dose\                                                                                1\. Significant reduction in V~30\ Gy~,[@b14-cmar-10-4853] V~25\ Gy~,[@b32-cmar-10-4853] V~20\ Gy~,[@b14-cmar-10-4853],[@b23-cmar-10-4853],[@b32-cmar-10-4853],[@b34-cmar-10-4853],[@b114-cmar-10-4853]--[@b118-cmar-10-4853] V~10\ Gy~,[@b14-cmar-10-4853],[@b22-cmar-10-4853],[@b115-cmar-10-4853] V~5\ Gy~,[@b14-cmar-10-4853],[@b22-cmar-10-4853],[@b32-cmar-10-4853],[@b34-cmar-10-4853],[@b35-cmar-10-4853],[@b59-cmar-10-4853],[@b114-cmar-10-4853]--[@b116-cmar-10-4853],[@b119-cmar-10-4853] D~mean~,[@b13-cmar-10-4853],[@b14-cmar-10-4853],[@b22-cmar-10-4853],[@b32-cmar-10-4853]--[@b35-cmar-10-4853],[@b59-cmar-10-4853],[@b114-cmar-10-4853]--[@b118-cmar-10-4853] D~max~[@b13-cmar-10-4853],[@b32-cmar-10-4853],[@b34-cmar-10-4853],[@b45-cmar-10-4853],[@b115-cmar-10-4853],[@b119-cmar-10-4853]\                                                                                                                                                                                                                                                                                                          1\. Studies demonstrated cardiac dose reduction in \>50% of studies. Some studies reported increased cardiac dose\                                              1\. Significant reduction in V~20\ Gy~,[@b14-cmar-10-4853] V~5\ Gy~,[@b14-cmar-10-4853],[@b114-cmar-10-4853] D~mean~,[@b14-cmar-10-4853],[@b59-cmar-10-4853],[@b114-cmar-10-4853] D~max~,[@b14-cmar-10-4853],[@b59-cmar-10-4853]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            1\. Studies demonstrated increase in LAD dose in \>50% of studies. Some studies reported decrease in LAD dose\                                              1\. Nonsignificant reduction in V~20\ Gy~,[@b13-cmar-10-4853] V~5\ Gy~,[@b13-cmar-10-4853],[@b114-cmar-10-4853] D~mean~,[@b114-cmar-10-4853] D~max~[@b13-cmar-10-4853]\
                   2. Prone setup proved to better spare lung, independently of breast size. This was found to be independent of breast size\            1. Nonsignificant reduction in V~20\ Gy~, V~10\ Gy~ [@b120-cmar-10-4853]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   2. Larger breast volumes demonstrated greater cardiac dose reduction. However, this was inconsistent for smaller breast volumes\                                2. Nonsignificant reduction in V~35\ Gy~,[@b174-cmar-10-4853] V~30\ Gy~,[@b120-cmar-10-4853],[@b175-cmar-10-4853] V~25\ Gy~,[@b116-cmar-10-4853] V~20\ Gy~,[@b116-cmar-10-4853],[@b120-cmar-10-4853] V~5\ Gy~,[@b22-cmar-10-4853],[@b116-cmar-10-4853] D~mean~,[@b32-cmar-10-4853],[@b34-cmar-10-4853],[@b116-cmar-10-4853],[@b174-cmar-10-4853] D~max~[@b34-cmar-10-4853],[@b116-cmar-10-4853],[@b119-cmar-10-4853]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        2. Prospective data demonstrated acceptable and comparable toxicities and clinical outcomes\                                                                2. Significant increase in D~mean~,[@b13-cmar-10-4853] D~max~[@b13-cmar-10-4853]\
                   3. Reduction in lung dose was not correlated to breast size\                                                                          2. Nonsignificant reduction in lung volume in field[@b13-cmar-10-4853],[@b22-cmar-10-4853],[@b35-cmar-10-4853],[@b119-cmar-10-4853],[@b121-cmar-10-4853]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   3. Prospective data demonstrated acceptable and comparable toxicities and clinical outcomes\                                                                     i. Significant increase in D~mean~[@b13-cmar-10-4853]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      3. Studied as part of breast conserving therapy\                                                                                                            3. Nonsignificant increase in V~40\ Gy~,[@b33-cmar-10-4853],[@b114-cmar-10-4853] V~20\ Gy~,[@b33-cmar-10-4853] D~mean~,[@b33-cmar-10-4853],[@b34-cmar-10-4853],[@b116-cmar-10-4853],[@b118-cmar-10-4853] D~max~[@b34-cmar-10-4853],[@b116-cmar-10-4853]\
                   4. Prospective data demonstrated acceptable and comparable toxicities and clinical outcomes\                                          3. Nonsignificant increase in lung volume in field[@b115-cmar-10-4853]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      4. Studied as part of breast conserving therapy\                                                                                                                &emspii. Nonsignificant increase in V~40\ Gy~,[@b32-cmar-10-4853] V~30\ Gy~,[@b118-cmar-10-4853] V~10\ Gy~,[@b22-cmar-10-4853] V~5\ Gy~,[@b22-cmar-10-4853],[@b35-cmar-10-4853] D~mean~[@b21-cmar-10-4853],[@b118-cmar-10-4853]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             4. Can be utilized in combination with IMRT or PBI                                                                                                          4. Comparable D~mean~,[@b115-cmar-10-4853] D~max~[@b115-cmar-10-4853],[@b116-cmar-10-4853]
                   5. Studied as part of breast conserving therapy\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  5. Can be utilized in combination with IMRT or PBI                                                                                                              3. Comparable V~20\ Gy~,[@b115-cmar-10-4853] V~10\ Gy~,[@b115-cmar-10-4853] V~5\ Gy~,~115,119~ D~mean~,[@b33-cmar-10-4853],[@b115-cmar-10-4853],[@b117-cmar-10-4853] D~max~[@b115-cmar-10-4853]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                   6. Can be utilized in combination with IMRT or PBT                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 i. Significant reduction in heart volume in field[@b121-cmar-10-4853]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      ii. Nonsignificant reduction in heart volume in field,[@b22-cmar-10-4853],[@b119-cmar-10-4853] maximum heart distance in field[@b35-cmar-10-4853]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  PBT              1\. All studies demonstrated a reduction in high dose to the lung\                                                                    1\. Significant reduction in V~20\ Gy~,[@b42-cmar-10-4853],[@b43-cmar-10-4853] V~5\ Gy~,[@b42-cmar-10-4853],[@b43-cmar-10-4853] D~mean~,[@b42-cmar-10-4853],[@b43-cmar-10-4853] D~max~,[@b43-cmar-10-4853] D~2%~ [@b44-cmar-10-4853]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       1\. All studies demonstrated cardiac dose reduction\                                                                                                            1\. Significant reduction in V~30\ Gy~,[@b43-cmar-10-4853] V~20\ Gy~,[@b42-cmar-10-4853],[@b43-cmar-10-4853] V~10\ Gy~,[@b42-cmar-10-4853] V~5\ Gy~,[@b42-cmar-10-4853],[@b43-cmar-10-4853] D~mean~,[@b42-cmar-10-4853]--[@b44-cmar-10-4853] D~max~[@b43-cmar-10-4853]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      1\. All studies demonstrated a reduction in dose to the LAD\                                                                                                1\. Significant reduction in V~20\ Gy~,[@b43-cmar-10-4853] V~10\ Gy~,[@b43-cmar-10-4853] V~5\ Gy~,[@b43-cmar-10-4853] D~mean~,[@b42-cmar-10-4853]--[@b44-cmar-10-4853] D~max~,[@b42-cmar-10-4853],[@b43-cmar-10-4853] D~2%~,[@b44-cmar-10-4853] D~0.2\ cc~[@b42-cmar-10-4853]\
                   2. All but one study demonstrated an increase in low dose to the lung\                                                                2. Nonsignificant reduction in V~20\ Gy~,[@b44-cmar-10-4853],[@b45-cmar-10-4853] V~5\ Gy~,[@b45-cmar-10-4853] D~mean~,[@b44-cmar-10-4853] integral dose[@b44-cmar-10-4853]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 2. Small prospective studies demonstrate feasibility of PBT with acceptable and comparable toxicities and clinical outcomes\                                    2. Nonsignificant reduction in V~22.5\ Gy~,[@b45-cmar-10-4853] V~20\ Gy~,[@b44-cmar-10-4853] V[@b5-cmar-10-4853] ^Gy^,[@b44-cmar-10-4853],[@b45-cmar-10-4853] D~mean~,[@b45-cmar-10-4853] D~2%~ [@b44-cmar-10-4853]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          2. Small prospective studies demonstrate feasibility of PBT with acceptable and comparable toxicities and clinical outcomes\                                2. Nonsignificant reduction in D~mean~, D~2%~[@b44-cmar-10-4853]
                   3. Small prospective studies demonstrate feasibility of PBT with acceptable and comparable toxicities and clinical outcomes\          3. Nonsignificant increase in V~10\ Gy~ [@b44-cmar-10-4853]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 3. Studied as part of breast conserving therapy\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             3. Studied as part of breast conserving therapy\                                                                                                            
                   4. Studied as part of breast conserving therapy\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  4. Can be utilized in combination with PBI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   4. Can be utilized in combination with PBI                                                                                                                  
                   5. Can be utilized in combination with PBI and BH/Gating                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

  IMRT             1\. Almost 50% of the dosimetric studies demonstrated reduction to high doses to the lung with an increase in low dose to the lung\   1\. Significant reduction in V~50\ Gy~,[@b48-cmar-10-4853],[@b122-cmar-10-4853] V~40\ Gy~,[@b123-cmar-10-4853],[@b124-cmar-10-4853] V~30\ Gy~,[@b124-cmar-10-4853]--[@b129-cmar-10-4853] V~25\ Gy~,[@b48-cmar-10-4853],[@b130-cmar-10-4853],[@b131-cmar-10-4853] V~20\ Gy~,[@b48-cmar-10-4853],[@b49-cmar-10-4853],[@b66-cmar-10-4853],[@b122-cmar-10-4853]--[@b128-cmar-10-4853],[@b132-cmar-10-4853]--[@b134-cmar-10-4853] V~13\ Gy~,[@b48-cmar-10-4853] V[@b10-cmar-10-4853] ^Gy^,[@b48-cmar-10-4853],[@b49-cmar-10-4853],[@b125-cmar-10-4853],[@b127-cmar-10-4853],[@b128-cmar-10-4853],[@b135-cmar-10-4853] V~5\ Gy~,[@b48-cmar-10-4853],[@b49-cmar-10-4853],[@b66-cmar-10-4853],[@b135-cmar-10-4853] V~90%~,[@b132-cmar-10-4853] D~mean~,[@b48-cmar-10-4853],[@b49-cmar-10-4853],[@b66-cmar-10-4853],[@b122-cmar-10-4853],[@b127-cmar-10-4853],[@b12-cmar-10-4853] [@b8-cmar-10-4853],[@b130-cmar-10-4853]--[@b132-cmar-10-4853],[@b134-cmar-10-4853]--[@b136-cmar-10-4853] D~max~,[@b49-cmar-10-4853],[@b66-cmar-10-4853],[@b122-cmar-10-4853],[@b132-cmar-10-4853] D2% [@b130-cmar-10-4853],[@b131-cmar-10-4853]\   1\. More than 50% of the dosimetric studies demonstrated dose reduction to the heart. Substantial number of studies also demonstrated increase in heart dose\   1\. Significant reduction in V~50\ Gy~,[@b48-cmar-10-4853] V~40\ Gy~,[@b123-cmar-10-4853],[@b124-cmar-10-4853] V~35\ Gy~,[@b176-cmar-10-4853] V~30\ Gy~,[@b26-cmar-10-4853],[@b42-cmar-10-4853],[@b124-cmar-10-4853]--[@b127-cmar-10-4853],[@b129-cmar-10-4853],[@b133-cmar-10-4853],[@b137-cmar-10-4853],[@b143-cmar-10-4853],[@b177-cmar-10-4853] V~25\ Gy~,[@b48-cmar-10-4853] V~20\ Gy~,[@b42-cmar-10-4853],[@b48-cmar-10-4853],[@b49-cmar-10-4853],[@b66-cmar-10-4853],[@b124-cmar-10-4853],[@b125-cmar-10-4853],[@b127-cmar-10-4853],[@b137-cmar-10-4853],[@b14-cmar-10-4853] [@b3-cmar-10-4853],[@b177-cmar-10-4853],[@b178-cmar-10-4853] V~13\ Gy~,[@b48-cmar-10-4853] V~10\ Gy~,[@b48-cmar-10-4853],[@b49-cmar-10-4853],[@b124-cmar-10-4853],[@b125-cmar-10-4853],[@b1-cmar-10-4853] [@b27-cmar-10-4853],[@b137-cmar-10-4853],[@b177-cmar-10-4853],[@b178-cmar-10-4853] V~5\ Gy~,[@b42-cmar-10-4853],[@b48-cmar-10-4853],[@b49-cmar-10-4853],[@b66-cmar-10-4853],[@b127-cmar-10-4853],[@b137-cmar-10-4853],[@b178-cmar-10-4853] D~mean~,[@b48-cmar-10-4853],[@b49-cmar-10-4853],[@b66-cmar-10-4853],[@b127-cmar-10-4853],[@b132-cmar-10-4853],[@b176-cmar-10-4853],[@b179-cmar-10-4853] D~max~,[@b48-cmar-10-4853],[@b49-cmar-10-4853],[@b66-cmar-10-4853],[@b127-cmar-10-4853],[@b132-cmar-10-4853],[@b176-cmar-10-4853],[@b179-cmar-10-4853] D~5%~,[@b123-cmar-10-4853] D~2%~[@b178-cmar-10-4853]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                1\. More than 50% of the dosimetric studies demonstrated dose reduction to the LAD. Substantial number of studies also demonstrated increase in LAD dose\   1\. Significant reduction in V~40\ Gy~,[@b124-cmar-10-4853] V~30\ Gy~,[@b66-cmar-10-4853],[@b124-cmar-10-4853] V~20\ Gy~,[@b66-cmar-10-4853],[@b124-cmar-10-4853] V~10\ Gy~,[@b124-cmar-10-4853] V~5\ Gy~,[@b66-cmar-10-4853] D~mean~,[@b66-cmar-10-4853],[@b79-cmar-10-4853],[@b124-cmar-10-4853] D~max~[@b66-cmar-10-4853],[@b180-cmar-10-4853]\
                   2. Clinically feasible\                                                                                                               2. Nonsignificant reduction in V~30\ Gy~,[@b137-cmar-10-4853],[@b138-cmar-10-4853] V~20\ Gy~,[@b129-cmar-10-4853],[@b131-cmar-10-4853],[@b137-cmar-10-4853]--[@b145-cmar-10-4853] V~10\ Gy~,[@b130-cmar-10-4853],[@b135-cmar-10-4853],[@b137-cmar-10-4853],[@b138-cmar-10-4853],[@b146-cmar-10-4853] V~5\ Gy~,[@b130-cmar-10-4853],[@b131-cmar-10-4853],[@b138-cmar-10-4853] V~4\ Gy~,~146~ D~mean~,~135,140,143--145,147~ D~max~[@b49-cmar-10-4853],[@b144-cmar-10-4853],[@b145-cmar-10-4853],[@b147-cmar-10-4853]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        2. Clinically feasible\                                                                                                                                         2. Nonsignificant reduction in V~50\ Gy~,[@b122-cmar-10-4853] V~30\ Gy~,[@b138-cmar-10-4853],[@b141-cmar-10-4853] V~25\ Gy~,[@b130-cmar-10-4853] V~20\ Gy~,[@b129-cmar-10-4853],[@b138-cmar-10-4853]--[@b140-cmar-10-4853],[@b142-cmar-10-4853],[@b145-cmar-10-4853] V~10\ Gy~,[@b130-cmar-10-4853],[@b138-cmar-10-4853] V~5\ Gy~,[@b130-cmar-10-4853],[@b138-cmar-10-4853] V~110%~,[@b139-cmar-10-4853] D~mean~,[@b122-cmar-10-4853],[@b140-cmar-10-4853],[@b146-cmar-10-4853],[@b147-cmar-10-4853] D~max~,[@b145-cmar-10-4853],[@b147-cmar-10-4853],[@b148-cmar-10-4853] D~2%~[@b130-cmar-10-4853]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        2. Prospective data demonstrated acceptable and comparable toxicities and clinical outcomes\                                                                2. Nonsignificant reduction in V~50\ Gy~,[@b122-cmar-10-4853] V~30\ Gy~,[@b141-cmar-10-4853] V~20\ Gy~,[@b141-cmar-10-4853] V~10\ Gy~,[@b141-cmar-10-4853] V~5\ Gy~,[@b141-cmar-10-4853] D~mean~[@b180-cmar-10-4853]\
                   3. Multiple techniques are available\                                                                                                 3. Significant increase in V~40\ Gy~,[@b136-cmar-10-4853] V~30\ Gy~,[@b136-cmar-10-4853] V~20\ Gy~,[@b49-cmar-10-4853] V~10\ Gy~,[@b49-cmar-10-4853],[@b124-cmar-10-4853],[@b126-cmar-10-4853],[@b140-cmar-10-4853],[@b141-cmar-10-4853] V~5\ Gy~,[@b49-cmar-10-4853],[@b123-cmar-10-4853],[@b124-cmar-10-4853],[@b126-cmar-10-4853],[@b135-cmar-10-4853] D~mean~,[@b49-cmar-10-4853],[@b123-cmar-10-4853],[@b124-cmar-10-4853],[@b126-cmar-10-4853],[@b135-cmar-10-4853] D~max~[@b132-cmar-10-4853]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       3. Multiple techniques available\                                                                                                                               3. Significant increase in V~40\ Gy~,[@b136-cmar-10-4853] V~30\ Gy~,[@b136-cmar-10-4853] V~20\ Gy~,[@b179-cmar-10-4853] V~10\ Gy~,[@b126-cmar-10-4853],[@b140-cmar-10-4853],[@b179-cmar-10-4853] V~5\ Gy~,[@b124-cmar-10-4853],[@b126-cmar-10-4853],[@b140-cmar-10-4853],[@b142-cmar-10-4853],[@b179-cmar-10-4853] D~mean~[@b124-cmar-10-4853],[@b126-cmar-10-4853],[@b179-cmar-10-4853]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    3. Studied as part of breast conserving therapy\                                                                                                            3. Significant increase in V~5\ Gy~,[@b124-cmar-10-4853] D~mean~,[@b49-cmar-10-4853],[@b136-cmar-10-4853],[@b179-cmar-10-4853] D~max~[@b49-cmar-10-4853]\
                   4. Studied as part of breast conserving therapy\                                                                                      4. Nonsignificant increase in V~20\ Gy~,[@b136-cmar-10-4853] V~16\ Gy~,[@b146-cmar-10-4853] V~10\ Gy~,[@b136-cmar-10-4853] V~5\ Gy~,[@b142-cmar-10-4853] D~mean~,[@b129-cmar-10-4853],[@b148-cmar-10-4853],[@b149-cmar-10-4853] D~60%~,[@b148-cmar-10-4853] D~30%~[@b148-cmar-10-4853]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      4. Studied as part of breast conserving therapy\                                                                                                                4. Nonsignificant increase in V~30\ Gy~,[@b141-cmar-10-4853] V~20\ Gy~,[@b123-cmar-10-4853],[@b131-cmar-10-4853],[@b141-cmar-10-4853],[@b144-cmar-10-4853],[@b175-cmar-10-4853] V~16\ Gy~,[@b146-cmar-10-4853] V~10\ Gy~,[@b126-cmar-10-4853],[@b141-cmar-10-4853],[@b149-cmar-10-4853] V~8\ Gy~,[@b146-cmar-10-4853] V~5\ Gy~,[@b123-cmar-10-4853],[@b126-cmar-10-4853],[@b127-cmar-10-4853],[@b13-cmar-10-4853] [@b1-cmar-10-4853],[@b141-cmar-10-4853],[@b143-cmar-10-4853],[@b149-cmar-10-4853],[@b180-cmar-10-4853] D~mean~,[@b123-cmar-10-4853],[@b126-cmar-10-4853],[@b129-cmar-10-4853],[@b144-cmar-10-4853],[@b148-cmar-10-4853],[@b149-cmar-10-4853] D~max~,[@b144-cmar-10-4853],[@b149-cmar-10-4853] D~min~,[@b142-cmar-10-4853] D~60%~,[@b148-cmar-10-4853] D~30%~[@b148-cmar-10-4853]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           4. Can be utilized in combination with IMRT or PBI                                                                                                          4. Nonsignificant increase in D~mean~[@b122-cmar-10-4853]
                   5. Can be utilized in combination with prone technique, BH/gating or PBI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          5. Can be utilized in combination with prone technique, BH/gating or PBI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  BH               1\. Almost 50% of studies demonstrated an increase in lung dose\                                                                      1\. Significant reduction in V~40\ Gy~,[@b150-cmar-10-4853] V~37\ Gy~,[@b63-cmar-10-4853] V~30\ Gy~,[@b151-cmar-10-4853] V~25\ Gy~,[@b63-cmar-10-4853],[@b152-cmar-10-4853] V~20\ Gy~,[@b64-cmar-10-4853],[@b143-cmar-10-4853],[@b150-cmar-10-4853]--[@b156-cmar-10-4853] V~15\ Gy~,[@b64-cmar-10-4853] V~10\ Gy~,[@b64-cmar-10-4853],[@b151-cmar-10-4853] V~5\ Gy~,[@b64-cmar-10-4853],[@b152-cmar-10-4853],[@b157-cmar-10-4853] V~50%\ of\ prescription~,[@b70-cmar-10-4853] D~mean~,[@b59-cmar-10-4853],[@b63-cmar-10-4853],[@b64-cmar-10-4853],[@b152-cmar-10-4853],[@b154-cmar-10-4853],[@b156-cmar-10-4853]--[@b159-cmar-10-4853] D~max~[@b63-cmar-10-4853],[@b152-cmar-10-4853],[@b155-cmar-10-4853],[@b158-cmar-10-4853]\                                                                                                                                                                                                                                                                                                                                                                                           1\. All but two studies demonstrated cardiac dose reduction\                                                                                                    1\. Significant reduction in V~40\ Gy~,[@b61-cmar-10-4853]--[@b63-cmar-10-4853],[@b150-cmar-10-4853],[@b181-cmar-10-4853] V~30\ Gy~,[@b56-cmar-10-4853],[@b64-cmar-10-4853]--[@b66-cmar-10-4853],[@b118-cmar-10-4853],[@b150-cmar-10-4853],[@b151-cmar-10-4853],[@b157-cmar-10-4853],[@b158-cmar-10-4853],[@b161-cmar-10-4853],[@b162-cmar-10-4853],[@b181-cmar-10-4853] V~25\ Gy~,[@b62-cmar-10-4853],[@b64-cmar-10-4853],[@b152-cmar-10-4853],[@b156-cmar-10-4853],[@b182-cmar-10-4853] V~20\ Gy~,[@b61-cmar-10-4853],[@b64-cmar-10-4853],[@b66-cmar-10-4853],[@b144-cmar-10-4853],[@b150-cmar-10-4853],[@b152-cmar-10-4853],[@b157-cmar-10-4853],[@b159-cmar-10-4853],[@b162-cmar-10-4853],[@b181-cmar-10-4853] V~18\ Gy~,[@b164-cmar-10-4853] V~15\ Gy~,[@b64-cmar-10-4853],[@b159-cmar-10-4853] V~10\ Gy~,[@b64-cmar-10-4853],[@b150-cmar-10-4853],[@b151-cmar-10-4853],[@b159-cmar-10-4853],[@b161-cmar-10-4853] V~5\ Gy~,[@b62-cmar-10-4853],[@b64-cmar-10-4853],[@b66-cmar-10-4853],[@b152-cmar-10-4853],[@b157-cmar-10-4853],[@b159-cmar-10-4853] V~2\ Gy~,[@b157-cmar-10-4853] V~50%\ of\ prescription\ dose~,[@b70-cmar-10-4853],[@b166-cmar-10-4853] D~5%~,[@b164-cmar-10-4853] D~10\ cc~,[@b161-cmar-10-4853] D~2\ cc~,[@b159-cmar-10-4853] D~mean~,[@b56-cmar-10-4853],[@b58-cmar-10-4853],[@b59-cmar-10-4853],[@b61-cmar-10-4853]--[@b63-cmar-10-4853],[@b65-cmar-10-4853],[@b66-cmar-10-4853],[@b118-cmar-10-4853],[@b150-cmar-10-4853],[@b152-cmar-10-4853],[@b153-cmar-10-4853],[@b156-cmar-10-4853]--[@b158-cmar-10-4853],[@b160-cmar-10-4853],[@b161-cmar-10-4853],[@b166-cmar-10-4853],[@b167-cmar-10-4853],[@b181-cmar-10-4853],[@b183-cmar-10-4853] D~max~[@b57-cmar-10-4853],[@b59-cmar-10-4853],[@b62-cmar-10-4853],[@b66-cmar-10-4853],[@b118-cmar-10-4853],[@b151-cmar-10-4853]--[@b153-cmar-10-4853],[@b155-cmar-10-4853],[@b156-cmar-10-4853],[@b158-cmar-10-4853],[@b159-cmar-10-4853],[@b184-cmar-10-4853]\   1\. All studies demonstrated a reduction in dose to the LAD\                                                                                                1\. Significant reduction in V~40\ Gy~,[@b154-cmar-10-4853] V~30\ Gy~,[@b66-cmar-10-4853],[@b158-cmar-10-4853] V~25\ Gy~,[@b152-cmar-10-4853],[@b156-cmar-10-4853] V~20\ Gy~,[@b66-cmar-10-4853],[@b152-cmar-10-4853] V~5\ Gy~,[@b66-cmar-10-4853],[@b152-cmar-10-4853],[@b154-cmar-10-4853] V~50%\ of\ prescription\ dose~,[@b70-cmar-10-4853] D~me\ an~,[@b13-cmar-10-4853],[@b59-cmar-10-4853],[@b65-cmar-10-4853],[@b66-cmar-10-4853],[@b150-cmar-10-4853],[@b152-cmar-10-4853],[@b154-cmar-10-4853],[@b156-cmar-10-4853],[@b158-cmar-10-4853],[@b160-cmar-10-4853], [@b162-cmar-10-4853],[@b166-cmar-10-4853],[@b167-cmar-10-4853],[@b183-cmar-10-4853] D~max~,[@b13-cmar-10-4853],[@b58-cmar-10-4853],[@b59-cmar-10-4853],[@b66-cmar-10-4853],[@b152-cmar-10-4853]--[@b154-cmar-10-4853],[@b156-cmar-10-4853],[@b158-cmar-10-4853] D~0.2\ cc~[@b166-cmar-10-4853]\
                   2. Clinically feasible with treatment times not exceeding 20 minutes\                                                                 2. Nonsignificant reduction in V~30\ Gy~,[@b155-cmar-10-4853] V~25\ Gy~,[@b160-cmar-10-4853] V~20\ Gy~,[@b56-cmar-10-4853],[@b61-cmar-10-4853]--[@b63-cmar-10-4853],[@b65-cmar-10-4853],[@b118-cmar-10-4853],[@b155-cmar-10-4853],[@b159-cmar-10-4853],[@b161-cmar-10-4853]--[@b167-cmar-10-4853] V~15\ Gy~,[@b155-cmar-10-4853],[@b159-cmar-10-4853] V~10\ Gy~,[@b62-cmar-10-4853],[@b153-cmar-10-4853],[@b155-cmar-10-4853],[@b159-cmar-10-4853],[@b161-cmar-10-4853] V~5\ Gy~,[@b62-cmar-10-4853],[@b66-cmar-10-4853],[@b154-cmar-10-4853],[@b159-cmar-10-4853],[@b161-cmar-10-4853] D~mean~,[@b57-cmar-10-4853],[@b62-cmar-10-4853],[@b65-cmar-10-4853],[@b66-cmar-10-4853],[@b150-cmar-10-4853],[@b153-cmar-10-4853],[@b161-cmar-10-4853],[@b163-cmar-10-4853],[@b165-cmar-10-4853],[@b166-cmar-10-4853],[@b168-cmar-10-4853] D~5%~[@b164-cmar-10-4853]\                                                                                                                                                                                                                                                               2. I maging studies demonstrated DIBH as optimal for greatest cardiac avoidance\                                                                                2. Nonsignificant reduction in V~50\ Gy~,[@b150-cmar-10-4853] V~40\ Gy~,[@b153-cmar-10-4853] V~30\ Gy~,[@b155-cmar-10-4853] V~25\ Gy~,[@b160-cmar-10-4853],[@b167-cmar-10-4853],[@b185-cmar-10-4853] V~20\ Gy~,[@b153-cmar-10-4853],[@b155-cmar-10-4853],[@b163-cmar-10-4853] V~15\ Gy~,~155,186~ V~10\ Gy~,[@b155-cmar-10-4853],[@b163-cmar-10-4853] V~5\ Gy~,[@b155-cmar-10-4853],[@b163-cmar-10-4853],[@b185-cmar-10-4853] V~50%\ of\ prescription\ dose~,[@b187-cmar-10-4853] D~mean~,[@b57-cmar-10-4853],[@b163-cmar-10-4853],[@b168-cmar-10-4853],[@b182-cmar-10-4853],[@b185-cmar-10-4853],[@b186-cmar-10-4853] D~max~,[@b150-cmar-10-4853],[@b163-cmar-10-4853],[@b181-cmar-10-4853],[@b186-cmar-10-4853]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           2. Clinically feasible with treatment times not exceeding 20 minutes\                                                                                       2. Nonsignificant reduction in V~50%\ of\ prescription\ dose~,[@b187-cmar-10-4853] D~mean~,[@b118-cmar-10-4853],[@b153-cmar-10-4853],[@b168-cmar-10-4853],[@b185-cmar-10-4853] D~max~,[@b65-cmar-10-4853],[@b150-cmar-10-4853],[@b160-cmar-10-4853],[@b163-cmar-10-4853],[@b185-cmar-10-4853],[@b186-cmar-10-4853] D~2%~,[@b163-cmar-10-4853],[@b186-cmar-10-4853] D~0.2\ cc~[@b162-cmar-10-4853]\
                   3. Multiple techniques available\                                                                                                     5. Significant increase in V~20\ Gy~,[@b66-cmar-10-4853] D~max~[@b66-cmar-10-4853],[@b158-cmar-10-4853]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    3. Clinically feasible with treatment times not exceeding 20 minutes\                                                                                           3. Same V~25\ Gy~ [@b163-cmar-10-4853]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      3. Studied as part of breast conserving therapy\                                                                                                            3. Comparable in field LAD volume[@b67-cmar-10-4853]
                   4. Studied as part of breast conserving therapy\                                                                                      6. Nonsignificant increase in V~20\ Gy~,[@b166-cmar-10-4853] V~5\ Gy~,[@b155-cmar-10-4853] V~90%\ of\ prescription~,[@b169-cmar-10-4853] V~95%\ of\ prescription~,[@b169-cmar-10-4853] V~100%\ of\ prescription~,[@b169-cmar-10-4853] D~mean~,[@b58-cmar-10-4853],[@b158-cmar-10-4853] D~max~[@b62-cmar-10-4853]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           4. Studied as part of breast conserving therapy\                                                                                                                4. Significant reduction in heart volume in field[@b62-cmar-10-4853],[@b63-cmar-10-4853],[@b65-cmar-10-4853],[@b150-cmar-10-4853],[@b156-cmar-10-4853],[@b158-cmar-10-4853],[@b161-cmar-10-4853],[@b164-cmar-10-4853]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       4. Can be utilized in combination with IMRT                                                                                                                 
                   5. Can be utilized in combination with IMRT                                                                                           7. Comparable in D~mean~[@b56-cmar-10-4853],[@b165-cmar-10-4853]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           5. Can be utilized in combination with IMRT                                                                                                                     5. Nonsignificant reduction in heart volume in field[@b155-cmar-10-4853],[@b160-cmar-10-4853]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
                                                                                                                                                         8. Significant reduction in lung volume in field[@b64-cmar-10-4853],[@b65-cmar-10-4853],[@b151-cmar-10-4853],[@b160-cmar-10-4853]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          6. Nonsignificant increase in heart volume in field[@b151-cmar-10-4853]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                         9. Nonsignificant reduction in lung volume in field[@b157-cmar-10-4853],[@b158-cmar-10-4853]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                         10. Significant increase in lung volume in field[@b62-cmar-10-4853],[@b158-cmar-10-4853],[@b164-cmar-10-4853]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       
                                                                                                                                                         11. Nonsignificant increase in lung volume in field[@b56-cmar-10-4853],[@b64-cmar-10-4853],[@b153-cmar-10-4853],[@b155-cmar-10-4853]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

  PBI              1\. All studies demonstrated reduction in lung dose\                                                                                  1\. Significant reduction in V~25\ Gy~,[@b86-cmar-10-4853] V~20\ Gy~,[@b4-cmar-10-4853],[@b86-cmar-10-4853] V~15\ Gy~,[@b86-cmar-10-4853] V~10\ Gy~,[@b4-cmar-10-4853],[@b86-cmar-10-4853],[@b170-cmar-10-4853] V~5\ Gy~,[@b4-cmar-10-4853],[@b86-cmar-10-4853] V~1\ Gy~,[@b86-cmar-10-4853] V~50%\ of\ prescription~,[@b86-cmar-10-4853] D~mean~[@b4-cmar-10-4853],[@b86-cmar-10-4853],[@b171-cmar-10-4853]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               1\. All studies demonstrated reduction in heart dose\                                                                                                           1\. Significant reduction in V~30\ Gy~,[@b86-cmar-10-4853] V~25\ Gy~,~4,86~ V~20\ Gy~,[@b4-cmar-10-4853],[@b79-cmar-10-4853],[@b86-cmar-10-4853] V~15\ Gy~,[@b86-cmar-10-4853] V~10\ Gy~,[@b4-cmar-10-4853],[@b79-cmar-10-4853],[@b86-cmar-10-4853] V~5\ Gy~,[@b4-cmar-10-4853],[@b86-cmar-10-4853] V~2.5\ Gy~,[@b86-cmar-10-4853] V~1\ Gy~,[@b86-cmar-10-4853] D~mean~,[@b4-cmar-10-4853],[@b86-cmar-10-4853],[@b171-cmar-10-4853] D~max~[@b87-cmar-10-4853]\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               1\. All studies demonstrated reduction in LAD dose\                                                                                                         1\. Significant reduction in D~mean~,[@b87-cmar-10-4853] D~max~[@b4-cmar-10-4853],[@b87-cmar-10-4853]\
                   2. PBI is limited to early stage patients meeting specific criteria\                                                                  2. Nonsignificant reduction in V~20\ Gy~,[@b79-cmar-10-4853],[@b172-cmar-10-4853] V~10\ Gy~,[@b79-cmar-10-4853],[@b87-cmar-10-4853],[@b172-cmar-10-4853] V~5\ Gy~,[@b79-cmar-10-4853],[@b87-cmar-10-4853],[@b172-cmar-10-4853] V~2.5\ Gy~,[@b86-cmar-10-4853] V~50%\ of\ prescription~,[@b173-cmar-10-4853] D~mean~,[@b24-cmar-10-4853],[@b87-cmar-10-4853],[@b172-cmar-10-4853] D~max~[@b87-cmar-10-4853]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  2. PBI is limited to early stage patients meeting specific criteria\                                                                                            2. Nonsignificant reduction in V~30\ Gy~,[@b188-cmar-10-4853] V~20\ Gy~,[@b172-cmar-10-4853] V~10\ Gy~,[@b172-cmar-10-4853] V~5\ Gy~,[@b172-cmar-10-4853] V~50%\ of\ prescription~,[@b173-cmar-10-4853] D~mean~,[@b24-cmar-10-4853],[@b87-cmar-10-4853],[@b172-cmar-10-4853] D~max~[@b87-cmar-10-4853]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       2. PBI is limited to early stage patients meeting specific criteria\                                                                                        2. Nonsignificant reduction in D~mean~,[@b24-cmar-10-4853] D~max~[@b24-cmar-10-4853]
                   3. Can be utilized in combination with prone technique, IMRT and PBI\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             3. Can be utilized in combination with prone technique, IMRT and PBI\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        3. Can be utilized in combination with prone technique, IMRT and PBI\                                                                                       
                   4. Multiple techniques available                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  4. Multiple techniques available                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             4. Multiple techniques available                                                                                                                            

  IORT             1\. One study demonstrated Nonsignificant reduction in lung dose\                                                                     1\. Nonsignificant reduction in D~mean~ (3.40 vs 0.03 Gy), D~max~ (53.00 vs 1.80 Gy)[@b99-cmar-10-4853]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     1\. One study demonstrated Nonsignificant reduction in heart dose\                                                                                              1\. Nonsignificant reduction in D~mean~ (1.00 vs 0.01 Gy), D~max~ (2.80 vs 1.00 Gy)[@b99-cmar-10-4853]                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       1\. No findings on LAD dose                                                                                                                                 1\. No findings on LAD dose
                   2. One study reported no lung toxicity with IORT\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 2. I ORT is limited to early stage patients meeting specific criteria\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
                   3. I ORT is limited to early stage patients meeting specific criteria\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            3. To date, there is limited clinical data supporting IORT\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
                   4. To date, there is limited clinical data supporting IORT\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       4. Can be utilized in combination with PBI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
                   5. Can be utilized in combination with PBI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
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**Abbreviations:** BH, breath-hold; DIBH, deep inspiration breath-hold; D, dose; IMRT, intensity-modulated radiation therapy; IORT, intraoperative radiation therapy; LAD, left anterior descending artery; PBI, partial breast irradiation; PBT, proton beam radiation therapy; RT, radiation therapy; V, volume.
